| 摘要 |
<p>1. Claims for the Contracting States : BE, CH, DE, FR, GB, IT, LU, NL, SE. An octahydro-1H-pyrrolo[2,3-g]isoquinoline of the general formula see diagramm : EP0010661,P42,F2 wherein R1 is hydrogen, (C1 -C7 )-alkyl, (C1 -C7 )-alkanoyl or benzoyl or phenyl-(C1 -C7 )-alkyl each of which is optionally substituted on the phenyl ring by halogen, trifluoromethyl, (C1 -C7 )-alkyl, (C1 -C7 )-alkoxy, nitro, amino, (C1 -C7 )-alkylamino or di-(C1 -C7 )-alkylamino, R2 and R3 independently of each other are hydrogen, (C1 -C7 )-alkyl, (C3 -C6 )-cycloalkyl, (C2 -C7 -alkenyl, (C1 -C7 )-alkanoyl or benzoyl, phenyl or phenyl-(C1 -C7 )-alkyl each of which is optionally substituted on the phenyl ring by halogen, trifluoromethyl, (C1 -C7 )-alkyl, (C1 -C7 )-alkoxy, nitro, amino, (C1 -C7 )-alkylamino or di-(C1 -C7 )-alkyl-amino and R4 is hydrogen, (C1 -C7 )-alkyl, hydroxy-(C1 -C7 )-alkyl, phenyl-hydroxy-(C1 -C7 )-alkyl, halophenyl-hydroxy-(C1 -C7 )-alkyl, (C1 -C7 )-alkylphenyl-hydroxy-(C1 -C7 )-alkyl, (C1 -C7 )-alkoxyphenyl-hydroxy-(C1 -C7 )-alkyl, (C1 -C7 )-alkoxy-(C1 -C7 )-alkyl, (C1 -C7 )-alkoxy-hydroxy-(C1 -C7 )-alkyl, (C1 -C7 )-alkanoyloxy-(C1 -C7 )-alkyl, (C1 -C7 )-alkoxycarbonyl-(C1 -C7 )-alkyl, (C2 -C7 )-alkenyl, (C3 -C6 )-cycloalkyl-(C1 -C7 )-alkyl, (C2 -C7 )-alkynyl, thienyl-(C1 -C7 )-alkyl, furyl-(C1 -C7 )-alkyl, (C1 -C7 )-alkanoyl-(C1 -C7 )-alkyl, (C3 -C6 )-cycloalkoxy-(C1 -C7 )-alkyl, (C3 -C6 )-cycloalkyl-hydroxy-(C1 -C7 )-alkyl, (C2 -C7 )-alkenyloxy-(C1 -C7 )-alkyl, N-(C1 -C7 )-alkyl-pyrrolidinyl-(C1 -C7 )-alkyl, trifluoroalkyl with 2 to 6 carbon atoms or phenoxy-hydroxy-(C1 -C7 )-alkyl, benzoyloxy-(C1 -C7 )-alkyl benzoyl-(C1 -C7 )-alkyl, phenyl-(C1 -C7 )-alkyl, phenylcarboxamido-(C1 -C7 )-alkyl, phenyl-(C2 -C7 )-alkenyl, phenoxy-(C1 -C7 )-alkyl or phenyl-N-imidazolonyl-(C1 -C7 )-alkyl each of which is optionally substituted on the phenyl ring by halogen, trifluoromethyl, (C1 -C7 )-alkyl, (C1 -C7 )-alkoxy, nitro, amino, (C1 -C7 )-alkylamino or di-(C1 -C7 )-alkylamino, or see diagramm : EP0010661,P43,F2 wherein R6 and R7 independently of each other are hydrogen or (C1 -C7 )-alkyl or together with the nitrogen atom are a 5- or membered saturated heterocyclic ring which can further contain as a ring member an oxygen atom or a nitrogen atom optionally substituted by (C1 -C7 )-alkyl or hydroxy-(C1 -C7 )-alkyl, and X is O or S, an optical or geometric isomer thereof or a pharmaceutically acceptable acid addition salt thereof. 1. Claims for the Contracting State : AT. A process for the manufacture of octahydro-1H-pyrrolo[2,3-g]isoquinolines of the general formula see diagramm : EP0010661,P47,F3 wherein R1 is hydrogen, (C1 -C7 )-alkyl, (C1 -C7 )-alkanoyl or benzoyl or phenyl-(C1 -C7 )-alkyl each of which is optionally substituted on the phenyl ring by halogen, trifluoromethyl, (C1 -C7 )-alkyl, (C1 -C7 )-alkoxy, nitro, amino, (C1 -C7 )-alkylamino or di-(C1 -C7 )-alkylamino, R2 and R3 independently of each other are hydrogen, (C1 -C7 )-alkyl, (C3 -C6 )-cycloalkyl, (C2 -C7 )-alkenyl, (C1 -C7 )-alkanoyl or benzoyl, phenyl or phenyl-(C1 -C7 )-alkyl each of which is optionally substituted on the phenyl ring by halogen, trifluoromethyl, (C1 -C7 )-alkyl, (C1 -C7 )-alkoxy, nitro, amino, (C1 -C7 )-alkylamino or di-(C1 -C7 )-alkylamino and R4 is hydrogen, (C1 -C7 )-alkyl, hydroxy-(C1 -C7 )-alkyl, phenyl-hydroxy-(C1 -C7 )-alkyl, halophenyl-hydroxy-(C1 -C7 )-alkyl, (C1 -C7 )-alkylphenyl-hydroxy-(C1 -C7 )-alkyl, (C1 -C7 )-alkoxyphenyl-hydroxy-(C1 -C7 )-alkyl, (C1 -C7 )-alkoxy-(C1 -C7 )-alkyl, (C1 -C7 )-alkoxy-hydroxy-(C1 -C7 )-alkyl, (C1 -C7 )-alkanoyloxy-(C1 -C7 )-alkyl, (C1 -C7 )-alkoxycarbonyl- (C1 -C7 )-alkyl, (C2 -C7 )-alkenyl, (C3 -C6 )-cycloalkyl-(C1 -C7 )-alkyl, (C2 -C7 )-alkynyl, thienyl-(C1 -C7 )-alkyl, furyl-(C1 -C7 )-alkyl, (C1 -C7 )-alkanoyl-(C1 -C7 )-alkyl, (C3 -C6 )-cycloalkoxy-(C1 -C7 )-alkyl, (C3 -C6)-cycloalkyl-hydroxy-(C1 -C7 )-alkyl, (C2 -C7 )-alkenyloxy-(C1 -C7 )-alkyl, N-(C1 -C7 )-alkyl-pyrrolidinyl-(C1 -C7 )-alkyl, trifluoroalkyl with 2 to 6 carbon atoms or phenoxy-hydroxy-(C1 -C7 )-alkyl, benzoyloxy-(C1 -C7 )-alkyl, benzoyl-(C1 -C7 )-alkyl, phenyl-(C1 -C7 )-alkyl, phenylcarboxamido-(C1 -C7 )-alkyl, phenyl-(C2 -C7 )-alkenyl, phenoxy-(C1 -C7 )-alkyl or phenyl-N-imidazolonyl-(C1 -C7 )-alkyl each of which is optionally substituted on the phenyl ring by halogen, trifluoromethyl, (C1 -C7 )-alkyl, (C1 -C7 )-alkoxy, nitro, amino, (C1 -C7 )-alkylamino or di-(C1 -C7 )-alkylamino, or see diagramm : EP0010661,P47,F2 wherein R6 and R7 independently of each other are hydrogen or (C1 -C7 )-alkyl or together with the nitrogen atom are a 5- or 6-membered saturated heterocyclic ring which can further contain as a ring member an oxygen atom or a nitrogen atom optionally substituted by (C1 -C7 )-alkyl or hydroxy-(C1 -C7 )-alkyl, and X is O or S, the optical and geometric isomers of these compounds and their pharmaceutically acceptable acid addition salts, characterized by a) for the manufacture of a compound of the general formula see diagramm : EP0010661,P47,F4 wherein R"4 is (C1 -C7 )-alkyl, (C1 -C7 )-alkoxy-(C1 -C7 )-alkyl or (C3 -C6 )-cyclo-alkyl-(C1 -C7 )-alkyl and R2 and R3 are as described previously, treating a compound of the general formula see diagramm : EP0010661,P48,F1 wherein R2 , R3 and R"4 are as described previously, with formaldehyde, or b) for the manufacture of a compound of formula Ia above, treating a compound of the general formula see diagramm : EP0010661,P48,F2 wherein R"4 is as described previously, with a compound of the general formula see diagramm : EP0010661,P48,F3 in the presence of a reducing agent, or with a compound of the general formula see diagramm : EP0010661,P48,F5 wherein R2 and R3 are as described previously, or a precursor thereof, or c) for the manufacture of a compound of the general formula see diagramm : EP0010661,P48,F7 wherein R2 and R3 are as described previously, N-demethylating a compound of formula Ia above wherein R"4 is methyl, or d) for the manufacture of a compound of the general formula see diagramm : EP0010661,P48,F8 wherein R'2 and R'3 independently of each other are hydrogen, (C1 -C7 )-alkyl, (C3 -C6 )-cycloalkyl, (C2 -C7 )-alkenyl or phenyl or phenyl-(C1 -C7 )-alkyl each of which is optionally substituted on the phenyl ring by halogen, trifluoromethyl, (C1 -C7 )-alkyl, (C1 -C7 )-alkoxy, nitro, amino, (C1 -C7 )-alkyl-amino or di-(C1 -C7 )-alkylamino, R'"4 is hydrogen, (C1 -C7 )-alkyl, (C1 -C7 )-alkoxy-(C1 -C7 )-alkyl, (C2 -C7 )-alkenyl, (C3 -C6 )-cycloalkyl-(C1 -C7 )-alkyl, (C2 -C7 )-alkynyl, thienyl-(C1 -C7 )-alkyl, furyl-(C1 -C7 )-alkyl, (C2 -C7 )-alkenyloxy-(C1 -C7 )-alkyl or phenyl-(C1 -C7 )-alkyl, phenyl-(C2 -C7 )-alkenyl or phenoxy-(C1 -C7 )-alkyl each of which is optionally substituted on the phenyl ring by halogen, trifluoro-methyl, (C1 -C7 )-alkyl, (C1 -C7 )-alkoxy, nitro, amino, (C1 -C7 )-alkylamino or di-(C1 -C7 )-alkylamino, or trifluoroalkyl with 2 to 6 carbon atoms and R1 is as described previously, treating a compound of the general formula see diagramm : EP0010661,P48,F4 wherein R1 , R'2 , R'3 and R'"4 are as described previously, with phosphorus pentasulphide, or e) for the manufacture of a compound of the general formula see diagramm : EP0010661,P48,F6 wherein R4-IV is hydroxy-(C1 -C7 )-alkyl, phenyl-hydroxy-(C1 -C7 )-alkyl, halophenyl-hydroxy-(C1 -C7 )-alkyl, (C1 -C7 )-alkyl-phenyl-hydroxy-(C1 -C7 )-alkyl, (C1 -C7 )-alkoxyphenyl-hydroxy-(C1 -C7 )-alkyl, (C1 -C7 )-alkoxy-hydroxy-(C1 -C7 )-alkyl, (C1 -C7 )-alkanoyloxy-(C1 -C7 )-alkyl, (C1 -C7 )-alkoxycarbonyl-(C1 -C7 )-alkyl, (C1 -C7 )-alkanoyl-(C1 -C7 )-alkyl, (C3 -C6 )-cycloalkoxy-(C1 -C7 )-alkyl, (C3 -C6 )-cycloalkyl-hydroxy-(C1 -C7 )-alkyl, N-(C1 -C7 )-alkyl-pyrrolidinyl-(C1 -C7 )-alkyl or phenyl-N-imidazolonyl-(C1 -C7 )-alkyl, phenoxy-hydroxy-(C1 -C7 )-alkyl, benzoyloxy-(C1 -C7 )-alkyl, benzoyl-(C1 -C7 )-alkyl or phenylcarboxamido-(C1 -C7 )-alkyl each of which is optionally substituted on the phenyl ring by halogen, trifluoromethyl, (C1 -C7 )-alkyl, (C1 -C7 )-alkoxy, nitro, amino, (C1 -C7 )-alkylamino or di-(C1 -C7 )-alkylamino, or see diagramm : EP0010661,P48,F9 and R1 , R2 , R3 , R6 and R7 are as described previously, cleaving off the protecting group or protecting groups in a compound of the general formula see diagramm : EP0010661,P49,F1 wherein R"2 and R"3 have the same significance as R2 and R3 except when R2 and R3 are (C1 -C7 )-alkanoyl or benzoyl optionally substituted on the phenyl ring by halogen, trifluoromethyl, (C1 -C7 )-alkyl, (C1 -C7 )-alkoxy, nitro, amino, (C1 -C7 )-alkyl-amino or di-(C1 -C7 )-alkylamino, R"2 and R"3 are in protected form, R4-V has the same significance as R4-IV , but in protected form, and R1 is as described previously, or f) for the manufacture of a compound of the general formula see diagramm : EP0010661,P49,F2 wherein R'1 is (C1 -C7 )-alkyl, (C1 -C7 )-alkanoyl or benzoyl or phenyl-(C1 -C7 )-alkyl each of which is optionally substituted on the phenyl ring by halogen, trifluoromethyl, (C1 -C7 )-alkyl, (C1 -C7 )-alkoxy, nitro, amino, (C1 -C7 )-alkylamino or di-(C1 -C7 )-alkylamino and R2 , R3 , R"4 and X are as described previously, substituting a compound of the general formula see diagramm : EP0010661,P49,F5 wherein R2 , R3 , R"4 and X are as described previously, at the pyrrole nitrogen atom, or g) for the manufacture of a compound of the general formula see diagramm : EP0010661,P49,F7 wherein R'4 is (C1 -C7 )-alkyl, hydroxy-(C1 -C7 )-alkyl, phenyl-hydroxy-(C1 -C7 )-alkyl, halophenyl-hydroxy-(C1 -C7 )-alkyl, (C1 -C7 )-alkylphenyl-hydroxy-(C1 -C7 )-alkyl, (C1 -C7 )-alkoxyphenyl-hydroxy-(C1 -C7 )-alkyl, (C1 -C7 )-alkoxy-(C1 -C7 )-alkyl, (C1 -C7 )-alkoxy-hydroxy-(C1 -C7 )-alkyl, (C1 -C7 )-alkanoyloxy-(C1 -C7 )-alkyl, (C1 -C7 )-alkoxycarbonyl-(C1 -C7 )-alkyl, (C2 -C7 )-alkenyl, (C3 -C6 )-cycloalkyl-(C1 -C7 )-alkyl, (C2 -C7 )-alkynyl, thienyl-(C1 -C7 )-alkyl, furyl-(C1 -C7 )-alkyl, (</p> |
